COMPANY

Attralus

Keywords: amyloidosis neurology neurodegenerative diseases antibody AT02 124I-AT-01 AT-02 124I-AT03

Location: Naples, FL · source · Oct 12, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Deal Bayer deal · amount not disclosed · announced Jan 12, 2026 Company release ↗
Source quote
- Jan 12, 2026 · Company release ↗
  “(Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for systemic amyloidosis, today announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m)”
Raise Undisclosed round · $56M · announced Feb 6, 2024 Company release ↗
Source quote
- Feb 6, 2024 · Company release ↗
  “Attralus Closes $56 Million Financing”

Raises announced in these releases: $56M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Feb 6, 2024 Raise Undisclosed round · $56M source ↗
Sep 21, 2023 Trial start Phase 2: A Study of AT-02 in Subjects With Systemic Amyloidosis. source ↗
Sep 1, 2022 Trial start Phase 1: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis source ↗
Nov 30, 2021 Trial start Phase 2: A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis source ↗
Nov 30, 2021 Trial start Phase 1: A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05951049	A Study of AT-02 in Subjects With Systemic Amyloidosis.	Phase 2	Active, not recruiting	Sep 21, 2023	Sep 28, 2026 (estimated)
NCT05235269	A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis	Phase 2	Completed	Nov 30, 2021	Feb 6, 2023 (actual)
NCT05521022	Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis	Phase 1	Unknown status (ClinicalTrials.gov)	Sep 1, 2022	Mar 1, 2025 (estimated)
NCT05201911	A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis	Phase 1	Completed	Nov 30, 2021	Sep 6, 2022 (actual)